12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OMS824: Phase I data

A Phase I trial in healthy volunteers showed that single ascending-doses of OMS824 were well tolerated and displayed a half-life consistent with...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >